Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
2.

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD.

Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17.

PMID:
24633809
3.

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik A.

Invest New Drugs. 2014 Aug;32(4):653-60. doi: 10.1007/s10637-014-0071-z. Epub 2014 Mar 7.

PMID:
24604265
4.

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A.

Clin Cancer Res. 2014 Mar 15;20(6):1656-65. doi: 10.1158/1078-0432.CCR-13-2506. Epub 2014 Feb 3.

5.

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.

Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD.

PLoS One. 2013;8(3):e58089. doi: 10.1371/journal.pone.0058089. Epub 2013 Mar 8.

6.

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ.

Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22.

7.

Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF.

Cancer. 2013 Mar 1;119(5):1042-9. doi: 10.1002/cncr.27859. Epub 2012 Nov 6.

8.

Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.

Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, Lorusso P, Brachmann R, Tong RK, Yan Y, Watts R, Bai S, Hegde PS.

Clin Cancer Res. 2012 Nov 1;18(21):6040-8. doi: 10.1158/1078-0432.CCR-12-1652. Epub 2012 Sep 7.

9.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

10.

Patient-derived tumour xenografts as models for oncology drug development.

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG.

Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. doi: 10.1038/nrclinonc.2012.61. Review.

11.

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.

Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR.

Invest New Drugs. 2013 Feb;31(1):115-25. doi: 10.1007/s10637-012-9812-z. Epub 2012 Mar 14.

PMID:
22415798
12.

Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.

Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A.

Clin Cancer Res. 2012 Apr 1;18(7):2048-55. doi: 10.1158/1078-0432.CCR-11-2813. Epub 2012 Feb 14.

13.

The many faces of wnt and pancreatic ductal adenocarcinoma oncogenesis.

Weekes CD, Winn RA.

Cancers (Basel). 2011 Sep 21;3(3):3676-86. doi: 10.3390/cancers3033676.

14.

A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.

Infante JR, Jones SF, Bendell JC, Spigel DR, Yardley DA, Weekes CD, Messersmith WA, Hainsworth JD, Burris HA 3rd.

Eur J Cancer. 2011 Jan;47(2):199-205. doi: 10.1016/j.ejca.2010.09.002. Epub 2010 Nov 2.

PMID:
21051221
15.

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.

Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA.

Invest New Drugs. 2011 Oct;29(5):1057-65. doi: 10.1007/s10637-010-9413-7. Epub 2010 Mar 23.

16.

Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen.

Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, Bociek G, Enke C, Bast M, Chan WC, Armitage JO; Nebraska Lymphoma Study Group.

J Clin Oncol. 2002 Feb 15;20(4):1087-93.

PMID:
11844834
17.

VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells.

Weekes CD, Kuszynski CA, Sharp JG.

Leuk Lymphoma. 2001 Feb;40(5-6):631-45.

PMID:
11426535
18.

Lymphoma cells associated with bone marrow stromal cells in culture exhibit altered growth and survival.

Weekes CD, Pirruccello SJ, Vose JM, Kuszynski C, Sharp JG.

Leuk Lymphoma. 1998 Sep;31(1-2):151-65.

PMID:
9720725
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk